Novavax reaffirms full year 2024 guidance; presents at J.P. Morgan conference

NOVAVAX INC

Reaffirmed full year 2024 financial guidance, no specific figures provided.
Preliminary expectations for combined R&D and SG&A expenses for 2025 and 2026 mentioned without numbers.
Presenting strategic updates at 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.